Non-Hodgkin Lymphoma

Pseudohyperkalemia: False Potassium Levels Occur in a Patient With Lymphoma

Pseudohyperkalemia: False Potassium Levels Occur in a Patient With Lymphoma

By

The patient's history and current blood work results indicated a dangerously high potassium level. But a meticulously handled redraw proved it false.

NHL: Adolescent BMI, Height Linked With Subtype Risks

NHL: Adolescent BMI, Height Linked With Subtype Risks

By

Higher body weight and increased height during adolescence increase the risk for developing certain subtypes of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma.

No Risk of Second Primary Malignancies in Patients With NHL Receiving Rituximab

No Risk of Second Primary Malignancies in Patients With NHL Receiving Rituximab

By

Survivors of non-Hodgkin lymphoma (NHL) exposed to rituximab do not have an increased risk for developing second primary malignancies.

Timing Matters for Pegfilgrastim Administration

Timing Matters for Pegfilgrastim Administration

By

The incidence of febrile neutropenia was significantly higher among patients who received pegfilgrastim prophylaxis on the same day.

Breakthrough Advance Announced in International Blood Cancer Drug Trial

By

Researchers announced a breakthrough advance in a world-first international clinical trial of a new drug to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma that is refractory or resistant to current chemotherapies.

Follow-up PET/CT more than 95% sensitive for non-Hodgkin lymphoma

By

BALTIMORE, MD—For more aggressive cases of non-Hodgkin lymphoma (NHL), posttreatment surveillance with molecular imaging could mean the early start of a new, life-saving treatment. This was presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2015 Annual Meeting.

ASCO: New strategies promising for chronic-lymphocytic leukemia and non-Hodgkin lymphoma

ASCO: New strategies promising for chronic-lymphocytic leukemia and non-Hodgkin lymphoma

Two new targeted treatments slow progression of chronic-lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma.

Changes in cancer epigenome implicated in chemotherapy resistance and lymphoma relapse

By

New research indicate that malfunctioning genes are only partly to blame for why treatment that was effective ultimately fails in many patients with the most common form of non-Hodgkin lymphoma.

Infertile men at a greater risk for all cancers

Infertile men at a greater risk for all cancers

Compared with the vasectomy and control groups, infertile men had a higher risk of testis cancer, non-Hodgkin lymphoma, and all cancers.

Intense exercise may decrease non-Hodgkin lymphoma risk

Intense exercise may decrease non-Hodgkin lymphoma risk

Intense physical activity throughout life is linked to a 30 percent reduction in risk.

Lifetime vigorous physical activity may be beneficial in lowering risk for non-Hodgkin lymphoma

Lifetime vigorous physical activity may be beneficial in lowering risk for non-Hodgkin lymphoma

Level of physical activity over a lifetime can impact risk for non-Hodgkin lymphoma (NHL).

Low vitamin D linked to worse prognosis in a type of non-Hodgkin lymphoma

Low vitamin D linked to worse prognosis in a type of non-Hodgkin lymphoma

By

A lower vitamin D levels prior to treatment for follicular lymphoma has been linked to earlier relapse and increased mortality, according to a new study.

Targeting survival protein may counter drug-resistance in non-Hodgkin lymphomas

By

Targeting a specific cell survival protein could be key to treating some lymphomas, including those with genetic defects that make them resistant to standard therapies.

Response to new drug in patients with lymphomas and advanced solid tumors

Patients with B-cell non-Hodgkin lymphomas and advanced solid tumors have responded to a new drug that is being tested for the first time in humans in a phase I clinical trial.

New drug for non-Hodgkin lymphoma and chronic leukemia succeeds in phase I

By

A new chemotherapy drug being investigated for its potency against two types of cancer was found to be effective in about one-third of the participants in a phase I study.

Inhibitor idelalisib active in non-Hodgkin lymphoma

Inhibitor idelalisib active in non-Hodgkin lymphoma

The phosphatidylinositol-3-kinase delta inhibitor idelalisib shows antitumor activity in patients with indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Genetic driver of Waldenström macroglobulinemia identified

By

In nearly one-third of patients with Waldenström macroglobulinemia, the disease is switched on by a specific genetic mutation. A new drug that blocks the defective gene can arrest the disease in animal models, according to research reported at the 2013 ASH Annual Meeting, in New Orleans.

Drug-antibody pair has promising activity in non-Hodgkin lymphoma

By

A toxin linked to a targeted monoclonal antibody has shown compelling antitumor activity in patients with non-Hodgkin lymphomas (NHLs) who were no longer responding to treatment, according to a new report.

Longer remissions with early stem cell transplants for non-Hodgkin lymphoma

By

Performing early stem cell transplants in patients with aggressive non-Hodgkin lymphoma does not improve overall survival in high-risk patients, according to a new study. However, early transplantation appears to be beneficial among the small group of patients who are at the very highest risk.

PET/CT better than bone marrow biopsy for lymphoma diagnosis

By

Assessing bone marrow involvement in persons with a new diagnosis of diffuse large B-cell lymphoma (DLBCL) is better accomplished with 18F-FDG positron emission tomography/computed tomography (PET/CT).

Antiretroviral therapy has not improved survival of HIV-associated lymphoma

By

Survival rates were stable for patients with HIV-associated lymphoma during the antiretroviral therapy (ART) era in the United States, according to a new study.

Ibrutinib shows great promise in lymphoma, leukemia

By

Oral ibrutinib demonstrated durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma in one study, and showed a high frequency of durable remissions in relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma in another study.

Nursing Safety Procedures Essential in Caring for Patients with NHL Receiving Radioimmunotherapy

By

Nurses play a critical role in promoting safety for patients with indolent forms of non-Hodgkin lymphoma receiving radioimmunotherapy, according to research presented at the ONS 38th Annual Congress.

Chronic fatigue more common after childhood leukemia, lymphoma

Chronic fatigue is more than three times more prevalent among adult survivors of childhood leukemia or lymphoma than among other adults.

Leukemia after chemotherapy is a growing risk

Persons who have undergone cytotoxic chemotherapy for certain cancers, notably non-Hodgkin lymphoma, may develop acute myeloid leukemia.

Epigenomic abnormalities predict survival of patients with non-Hodgkin lymphoma

By

Abnormal epigenetic changes can change the expression of genes. Researchers hope to control the harmful epigenomic changes to turn down cancer itself or perhaps sensitize cancers to existing drugs.

Novel drug targets aggressive form of non-Hodgkin lymphoma

By

A new experimental drug therapy has been developed to target activated B-cell diffuse large B-cell lymphoma.

Ibrutinib may be a breakthrough for treatment of a rare lymphoma

Interim results confirmed the "unprecedented" single-agent activity of ibrutinib in relapsed or refractory mantle cell lymphoma.

FDA Update November/December 2012

Paclitaxel protein-bound particles for injectable suspension, 90-minute infusion of rituximab, omacetaxine mepesuccinate receive FDA approval

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs